NCT04203927 (EJB051) is a EARLY_PHASE1 clinical trial of Empagliflozin 25 MG in Type2 Diabetes, sponsored by University of Virginia.

Who is sponsoring NCT04203927?

NCT04203927 is sponsored by University of Virginia.

What drugs are being tested in NCT04203927?

Interventions in NCT04203927: Empagliflozin 25 MG.

What condition does NCT04203927 study?

NCT04203927 studies Type2 Diabetes, Insulin Sensitivity.

Is NCT04203927 still recruiting?

NCT04203927 is currently status unknown. Last updated 10 February 2022.

Last reviewed 2022-02-10 · How we verify

NCT04203927: EJB051

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

Status unknown EARLY_PHASE1 Last updated 10 February 2022

What this trial tests

EARLY_PHASE1 trial testing Empagliflozin 25 MG in Type2 Diabetes in 50 participants. Status unknown.

Timeline

1 February 2020

Primary endpoint
30 October 2023

30 November 2023

Quick facts

Lead sponsor	University of Virginia
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	50
Start date	1 February 2020
Primary completion	30 October 2023
Estimated completion	30 November 2023
Sites	1 location across United States

Drugs / interventions tested

Empagliflozin 25 MG — full drug profile →

Conditions studied

Type2 Diabetes — all drugs for Type2 Diabetes →
Insulin Sensitivity — all drugs for Insulin Sensitivity →

Sponsor

University of Virginia

Who can join

Adults 18 to 60, any sex, with Type2 Diabetes or Insulin Sensitivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim is to test in T2DM patients, whether, compared to placebo, 12 weeks of SGLT-2 inhibitor improves post-absorptive, post-insulin infusion or postprandial insulin action to enhance Cardiac Muscle vascular function and whether changes correlate with improved GV or postprandial hyperglycemia

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hypoxia signaling in human health and diseases: implications and prospects for therapeutics.
Luo Z, Tian M, Yang G, Tan Q, et al · · 2022 · cited 326× · PMID 35798726 · DOI 10.1038/s41392-022-01080-1

Verify or expand the search:

Other trials of Empagliflozin 25 MG

Trials testing the same drug.

NCT07053306 — SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia · Phase 1 · recruiting
NCT07053293 — SGLT2i, Hepatic Glucose Production, and SNS · EARLY_PHASE1 · recruiting
NCT05715814 — meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis · Phase 3 · recruiting
NCT06578676 — To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults · Phase 1 · recruiting
NCT06249932 — Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease · Phase 4 · recruiting

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting

Other University of Virginia trials

Trials by the same sponsor.

NCT05880355 — Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI · EARLY_PHASE1 · not yet recruiting
NCT07405645 — Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy · NA · recruiting
NCT07146685 — Effect of Local Anesthetic Concentration on Rebound Pain: A Randomized Control Study · Phase 4 · not yet recruiting
NCT07298941 — Resilience Enhancement Following Sleep Treatment · Phase 2 · recruiting
NCT07036315 — Meaning in Music-Based Pain Modulation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04203927 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Virginia
Last refreshed: 10 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04203927.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing